Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...

This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Please provide your email address to receive an email when new articles are posted on . Hyqvia is an immune globulin infusion (human) 10% solution. It was previously approved by the EC for primary ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- ...

Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory ...